UnitedHealth Group Incorporated

UnitedHealth Group is shifting its Medicare Advantage strategy to prioritize profitability over membership expansion, expecting 2026 enrollment to decline by approximately 1.1 million members due to targeted exits from unprofitable plans. Medicare margins are now expected to finish the year above 3%, reflecting tighter benefit design, pricing actions, and a more favorable membership mix, while the company expects Medicare medical cost trends to come below the initial estimate of near 10%. UnitedHealth's consolidated medical care ratio improved to 86.7% in the second quarter from 89.4% a year ago, and the company raised its 2026 adjusted EPS outlook to $19.50-$20. The Zacks Consensus Estimate for UnitedHealth's 2026 earnings is pegged at $19.69 per share, implying 20.4% growth from the year-ago period, and the stock currently carries a Zacks Rank #1 (Strong Buy).

UnitedHealth Group has received a Zacks Rank of 1, or Strong Buy, driven by a 7.1% increase in the Zacks Consensus Estimate for current-year earnings over the past month to $19.69 per share. The stock also carries an average brokerage recommendation of 1.39 based on 27 analysts, with 20 Strong Buy and three Buy ratings. Zacks notes that brokerage recommendations often carry a positive bias, while its own rank is tied to earnings estimate revisions. The company's growing analyst optimism over earnings prospects could support near-term stock gains.

UnitedHealth Group's board authorized a cash dividend of US$2.32 per share payable September 22, 2026, while outlining further exits from certain Medicare Advantage plans and updated margin expectations. The company plans to exit plans covering more than 600,000 members and expects a 1.1 million enrollment decline by 2026, targeting Medicare margins above 3%. Management also raised its 2026 adjusted EPS outlook, supported by lower medical costs. The company projects $498.6 billion revenue and $23.5 billion earnings by 2029, requiring 3.5% yearly revenue growth and a roughly $9.4 billion earnings increase from $14.1 billion today.

UnitedHealth Group reported second-quarter results showing its medical care ratio fell to 86.7% from 89.4% a year ago, helping operating earnings rise 55% and prompting the company to raise its 2026 adjusted EPS guidance. The quarter included $860 million of favorable prior-period medical development, while commercial medical costs are increasing at a rate exceeding 11% due to higher provider billing and coding intensity and specialty drug costs. Elevance Health's second-quarter benefit expense ratio was 89.7%, up 80 basis points year over year, but the company raised its 2026 adjusted EPS guidance to at least $27. CVS Health's Aetna business benefited from lower medical costs in the second quarter, leading to an earnings beat and raised 2026 adjusted EPS guidance of $7.90 to $8.10. UnitedHealth shares have risen 47.9% in the past 12 months, and the stock trades at a forward price-to-earnings ratio of 18.83X compared with the industry average of 16.48X.

Pacira BioSciences reported second quarter 2026 total revenues of $192.4 million, a 6% increase over the prior year, and updated full-year guidance to $735 million to $760 million following the divestiture of iovera to Zimmer Biomet. EXPAREL net sales rose 3% to $147.8 million, ZILRETTA sales grew 4% to $32.6 million, and iovera sales increased 21% to $6.8 million. The company highlighted UnitedHealthcare's decision to provide separate reimbursement for EXPAREL outside the surgical bundle, bringing total covered lives to over 150 million, and noted that ZILRETTA was placed on UnitedHealthcare's preferred drug list. Pacira expects top-line data from three registrational studies later this year: the iovera spasticity study, the ZILRETTA shoulder osteoarthritis study, and Part A of the Phase 2 PCRX-201 study.

A growing number of companies are raising their profit outlooks despite macroeconomic uncertainty. More S&P 500 firms are lifting guidance than cutting it, and Wall Street analysts have raised third-quarter earnings estimates for the index for the second consecutive quarter. Argus research analyst Christine Dooley views consistent guidance raises as a catalyst for market-beating returns. Among the companies that have raised guidance in the second quarter so far are Cheesecake Factory, Ford, General Motors, Hasbro, Starbucks, Coca-Cola, Charles Schwab, PayPal, US Bancorp, ASML, Seagate Technology, Supermicro Computer, Bristol Myers Squibb, Johnson & Johnson, UnitedHealth Group, 3M, Lockheed Martin, Northrop Grumman, United Airlines, and United Parcel Service.

Janus Henderson Investors’ Forty Fund highlighted UnitedHealth Group as a top relative contributor in the second quarter of 2026, citing faster-than-expected progress on a turnaround plan led by returning former CEO Stephen Hemsley. The fund, which returned 19.00% for the quarter versus the Russell 1000 Growth Index’s 16.74%, said UnitedHealth exceeded its first-quarter earnings targets after announcing cost management, operational improvements, and margin expansion initiatives. The company has also disclosed significant AI investments aimed at boosting customer engagement and productivity. UnitedHealth shares closed at approximately $414.40 on July 31, 2026, giving it a market capitalization of about $378.61 billion.

UnitedHealth Group's analyst fair value estimate has risen from $424.23 to $475.23, a 12% increase driven by Q2 earnings, Medicare Advantage and Optum Health updates, and refreshed 2026 earnings models. Several large firms raised price targets, with Wells Fargo moving from $485 to $526, Morgan Stanley from $468 to $529, and BofA from $475 to $512, citing better Medical Loss Ratio performance and Optum Health margin recovery. Revenue growth assumptions shifted from 3.12% to 3.47%, net profit margin from 4.43% to 4.71%, and future P/E multiple from 21.81x to 22.52x, while the discount rate remained near 7.11%. Bearish analysts flagged higher commercial costs and structural risks at Optum Health and Optum Insight, though near-term earnings risk is seen as more balanced.

UnitedHealth Group reported second-quarter 2026 adjusted earnings of $6.38 per share, beating the Zacks Consensus Estimate of $4.94 and rising 56.4% year over year, while revenues edged up 0.4% to $112 billion. The adjusted medical care ratio improved to 86.7% from 89.4% a year earlier, reflecting stronger pricing and better cost management, and medical costs fell to $75.4 billion from $78.6 billion. Management raised its full-year 2026 adjusted earnings outlook to a range of $19.50 to $20 per share, marking the second consecutive quarter of guidance increases. The stock has gained 29.9% year to date, outperforming the industry's 25.8% growth and the S&P 500's 7.8% rise, though it now trades at a forward price-to-earnings multiple of 20.39 times, above its five-year median of 19.20 times. Despite ongoing regulatory scrutiny and expected membership declines, the company returned more than $13 billion to shareholders in 2025 through dividends and buybacks, and it currently carries a Zacks Rank of 1, or Strong Buy.

UnitedHealth Group announced a $4 million commitment to expand the University of Tennessee Health Sciences' health hub network from five to 13 locations across Tennessee by the end of 2027. The funding, provided through the United Health Foundation with technical assistance from UnitedHealth Group, builds on nearly $2 million in support since 2022 and aims to reach 200,000 residents. The health hubs offer preventive care, chronic condition management, and health education in community settings, having already served more than 4,000 people through over 20,000 visits. The expansion is part of UnitedHealth Group's Communities of Health initiative, which launched with a $20 million commitment in 2026 to support community-based health models nationwide. The partnership will also strengthen rural health workforce pathways through collaborations with UT Health Sciences' nursing and medicine colleges.

Zacks Investment Research recommends three Dow blue-chip stocks—3M, Travelers, and UnitedHealth Group—following their solid second-quarter 2026 earnings results. 3M raised its full-year adjusted earnings guidance to a range of $8.80 to $8.95 per share, up from $8.50 to $8.70 previously, and expects adjusted total revenue growth above 4.5%. Travelers reported a 14% increase in after-tax net investment income to $883 million and projects a full-year 2026 underwriting expense ratio of approximately 28.5%. UnitedHealth Group lifted its 2026 adjusted EPS outlook to between $19.50 and $20.00, up from more than $18.25, with revenues anticipated above $439 billion. Each stock carries a favorable Zacks Rank, with UnitedHealth at Strong Buy and the other two at Buy.

Three dividend-paying stocks have vastly outperformed the broader market this year. ExxonMobil shares are up around 29% in 2026, UnitedHealth Group has gained 28%, and Texas Instruments has surged approximately 62%, all well ahead of the S&P 500's over 8% rise. ExxonMobil trades at 14 times forward earnings and yields 2.7%, while UnitedHealth yields 2.2% and has raised its payout by 60% over five years. Texas Instruments posted quarterly revenue of $5.5 billion, up 23% year over year, with net income rising 53% to just under $2 billion, driven by strong demand from data centers investing in artificial intelligence.

UnitedHealth Group and Intuitive Surgical both reported earnings that beat Wall Street expectations in the same week of July, yet their stocks moved in opposite directions. UnitedHealth posted adjusted earnings of $6.38 a share versus the $4.90 expected, with revenue rising to $112 billion, and raised its full-year profit forecast to $19.50 to $20 a share, sending its stock up as much as 8%. Intuitive Surgical saw revenue rise 19% to $2.89 billion and adjusted profit of $2.80 a share against the $2.50 estimate, but its stock fell as much as 13% after the company said it now expects full-year procedure growth near the middle of its unchanged 13.5% to 15.5% range, rather than the higher end previously implied. The medical cost ratio at UnitedHealth improved to 86.7% from 89.4% a year ago, while Intuitive Surgical confirmed that insurance-driven delays in care and GLP-1 weight-loss drugs are cutting into bariatric surgery volume, with U.S. procedure growth slowing to 12% from 14% in the prior quarter. Hedge fund data from Insider Monkey showed both stocks losing support before the reports, with UnitedHealth held by 130 funds at the end of the first quarter of 2026, down from 145, and Intuitive Surgical held by 103 funds, down from 109.

Mark Farrah Associates has released a comparative analysis of the top Administrative Services Only companies in Maryland, identifying UnitedHealth, CareFirst, CVS, and Cigna as the four leading administrators based on number of contracts. Together, these four companies cover 98 percent of the state's self-insured marketplace. CareFirst is the largest administrator in Maryland, while UnitedHealth covers employers in all counties and is the top administrator in six of those counties. CVS and Cigna also maintain a large ASO presence for employer contracts but do not cover as many counties as CareFirst and UnitedHealth.

UnitedHealth Group has been upgraded to a Zacks Rank #1, or Strong Buy, driven by a significant upward revision in its earnings estimates. The consensus estimate for the current quarter has risen 8.1% over the last 30 days to $3.90 per share, with four analysts raising their forecasts against one lowering. For the full year, the estimate has climbed 7.29% to $19.23 per share, supported by nine positive revisions and no negative ones. The stock has gained 6.6% over the past four weeks, reflecting investor confidence in the improving outlook for the largest U.S. health insurer.

A new survey from Fishbone Advisors finds that institutional investors believe healthcare's AI narrative is overblown, with 48% to 67% of investors in every subsector saying management overemphasizes AI relative to its actual financial contribution. The quarterly Fishbone Healthcare Benchmarking Study, which surveyed 75 institutional investors active in healthcare, also shows that AI has yet to register as a material valuation driver in any subsector, a result unchanged on retest six months later. Eli Lilly leads the first published investor-assigned AI scores for 30 large-cap healthcare companies at plus 78, followed by UnitedHealth at plus 72 and Moderna at plus 64. Healthcare specialists are the least persuaded, with only 33% expecting AI to significantly influence valuations within three years, compared to 51% of generalist investors. Despite the skepticism, 81% of surveyed investors say they are positive on healthcare over the coming year.

Several stocks made notable moves this week. HCA Healthcare fell 6.7% on Tuesday after releasing preliminary second-quarter results and cutting its full-year 2026 profit guidance. UnitedHealth rose 5.1% on Thursday after reporting second-quarter earnings that surpassed Wall Street expectations, driven by improved profitability. CrowdStrike gained 9.8% on Tuesday after U.S. and international security agencies issued a joint warning about Russian state-sponsored cyber threats targeting critical infrastructure. RXO rose 4.2% on Monday after Stifel raised its price target on the stock to $30 from $22 while maintaining a Buy rating. Enovis rose 3.6% on Monday after announcing the U.S. launch of CT-RevitL, a new veterinary laser therapy system from its Companion Animal Health business.

Wall Street closed lower on Thursday, dragged down by technology stocks, as investors assessed second-quarter earnings and a batch of economic data. The Dow Jones Industrial Average fell 0.2% to 52,553.32, the Nasdaq Composite declined 1.5% to 25,881.95, and the S&P 500 lost 0.5% to 7,533.77. Among the S&P 500's 11 sectors, the Communication Services Select Sector SPDR fell 2.9%, the Information Technology Select Sector SPDR dropped 1.8%, and the Consumer Discretionary Select Sector SPDR slipped 0.3%, while the Consumer Staples Select Sector SPDR rose 2.9%. The CBOE Volatility Index increased 6.8% to 16.73. In earnings, UnitedHealth Group reported second-quarter earnings of $6.38 per share on revenues of $112.03 billion, Abbott Laboratories posted earnings of $1.31 per share on revenues of $12.59 billion, and J.B. Hunt Transport Services earned $1.91 per share on revenues of $3.5 billion, with all three beating estimates and their stocks rising 1.2%, 10.7%, and 8%, respectively. On the economic front, retail sales rose 0.2% in June, pending home sales fell 5.4%, initial jobless claims dropped to 208,000, and the Philly Fed Index surged to 41.1.

UnitedHealth Group raised its full-year adjusted earnings outlook after second-quarter profit exceeded Wall Street expectations, sending shares up as much as 10.3% in their largest intraday gain since April. The company now expects adjusted earnings of $19.50 to $20 per share this year, up from a prior forecast of more than $18.25 and above analyst estimates. A closely watched measure of medical costs also performed better than projected, while quarterly profit topped the highest estimate in a Bloomberg survey. Chief Financial Officer Wayne DeVeydt said improving medical-cost trends in the first half gave the company greater confidence to raise its outlook, and the updated forecast could provide a starting point for increasing profits next year at the company's historical target rate of 13% to 16% average annual earnings-per-share growth. Shares of Humana and CVS Health also advanced following the report.

The semiconductor sell-off extended into a fourth session on Thursday, with memory chip stocks taking another heavy beating after Taiwan Semiconductor Manufacturing raised its capital expenditure forecast. Taiwan Semi beat earnings estimates but fell 4.6% after announcing it would spend between $60 billion and $64 billion this year, up from a prior forecast of $52 billion to $56 billion, and committed another $100 billion to Arizona chipmaking facilities. SK Hynix cratered 9.1%, adding to Wednesday's 13.2% plunge and leaving the stock down roughly 30% from recent post-IPO highs, while Micron Technology dropped 6.3%, Nvidia fell 2.7%, and Broadcom slid 3.6%. The Nasdaq Composite dropped 0.9%, the S&P 500 fell 0.3%, and the Dow Jones Industrial Average limited its decline to just 0.1% as healthcare stocks provided a cushion. UnitedHealth Group bounced 3.6% after crushing earnings estimates and raising guidance, and Abbott Laboratories soared 12.5% on a beat-and-raise performance, offsetting a 4.6% drop in Goldman Sachs and a 3.6% slide in Caterpillar.

U.S. stocks were mixed, with the Dow Jones Industrial Average rising to a one-week high while the Nasdaq 100 fell to a one-week low, as a selloff in chipmakers and AI-infrastructure stocks weighed on the broader market. The iShares Semiconductor ETF dropped more than 2%, with Sandisk down over 8% and ARM Holdings down over 7%, following a 6% plunge in South Korea's Kospi Index driven by sharp losses in SK Hynix and Samsung Electronics. UnitedHealth Group jumped 4% after reporting second-quarter adjusted earnings per share of $6.38, well above the consensus of $4.89, and raising its full-year adjusted EPS estimate to $19.50 to $20.00, while Abbott Laboratories surged more than 11% after lifting its full-year adjusted EPS forecast to a range of $5.45 to $5.60. Stronger-than-expected U.S. economic data, including a drop in weekly initial jobless claims to a 10-week low of 208,000 and a Philadelphia Fed business outlook survey rising to a 4.5-year high of 41.4, pushed the 10-year Treasury yield up 3 basis points to 4.58%. WTI crude oil prices rose nearly 1% after the U.S. launched fresh airstrikes on Iran and struck a sanctioned Iranian oil tanker in the Persian Gulf, with President Trump pledging to intensify bombardment until Iran stops attacking ships in the Strait of Hormuz.

UnitedHealth Group reported second quarter earnings on Thursday, raising its full-year outlook alongside $112 billion in quarterly revenue, sending its stock higher. Mizuho Americas healthcare equity strategist Jared Holz called it the best quarter out of the company and possibly the entire managed care industry in three to four years, noting Medicare Advantage is in a really good spot. He added that even assuming 20% annual earnings growth, well above the historical low-to-mid teens, the stock is trading at 15 to 16 times a 2028 number. The read across for other companies, according to Holz, is that Medicare Advantage is where you want to be, while commercial insurance and Medicaid remain more challenged.

Magellan Global Opportunities Fund highlighted UnitedHealth Group as a top contributor in the second quarter of 2026, citing a recovery driven by strong first-quarter results. The medical care ratio improved to 83.9% from 84.8% a year earlier, prompting management to raise full-year 2026 adjusted earnings per share guidance. The fund noted that UnitedHealth prioritized margin recovery over membership growth, including trimming Medicare Advantage membership and restoring operational discipline at Optum Health. Softer industry-wide medical cost trends and a larger-than-proposed 2027 Medicare Advantage rate increase further supported sentiment. UnitedHealth shares closed at $418.52 on July 15, 2026, with a one-month return of 4.38% and a 52-week gain of 45.28%, giving the company a market capitalization of $380.08 billion.

U.S. stock index futures were mixed on Thursday as UnitedHealth Group jumped 7.6% in premarket trading after reporting stronger-than-expected second-quarter results, while semiconductor stocks fell despite Taiwan Semiconductor Manufacturing Co. posting a record quarterly profit. UnitedHealth reported adjusted earnings of $6.38 per share, comfortably ahead of analyst estimates, and revenue that also exceeded forecasts. TSMC’s second-quarter profit surged 77% year-on-year to a record level, with earnings per share of $4.31 beating estimates of $3.80, but its shares fell about 4% as investors weighed an expanded capital expenditure plan and potential near-term margin pressure. The cautious reaction spread across the chip sector, with Nvidia slipping 1.3%, and AMD, Intel, and Micron Technology falling between 1.9% and 2.7%. Abbott Laboratories climbed 4.4% after beating expectations on both revenue and earnings, while GE Aerospace slipped 4.3% despite topping Wall Street estimates, and U.S. Bancorp declined 2.4% even after reporting record quarterly revenue and earnings that exceeded expectations.

UnitedHealth shares surged more than 7% in premarket trading after the health insurance giant reported better-than-expected second-quarter results and hiked its full-year earnings outlook. The company posted adjusted earnings of $6.38 per share on revenue of $112.03 billion, exceeding analyst forecasts of $4.90 per share and $110.85 billion, respectively. Taiwan Semiconductor Manufacturing fell 4% despite beating earnings estimates, as it raised full-year capital expenditures to between $60 billion and $64 billion and announced an additional $100 billion investment in Arizona. AtaiBeckley soared 34.5% after Eli Lilly agreed to acquire the psychedelic drugmaker for $2.8 billion, or $6.75 per share in cash, with up to an additional $2.50 per share contingent on milestones. GE Aerospace dropped 4% even after topping second-quarter expectations with adjusted earnings of $2.02 per share on revenue of $12.63 billion and raising its full-year guidance. United Airlines declined more than 3% as softer-than-expected third-quarter guidance of $2.50 to $3.50 per share overshadowed an earnings beat, and the carrier also flagged $6 billion in added fuel costs. J.B. Hunt Transport Services gained nearly 7% after reporting earnings of $1.73 per share, beating estimates by 18 cents, while revenue of $3.5 billion was in line with expectations. AeroVironment rose nearly 2% following an upgrade to outperform at Raymond James, and Rocket Companies added 2% after Morgan Stanley raised its price target to $19.

UnitedHealth Group has a strong chance of beating earnings estimates again in its next report, according to Zacks Investment Research. The largest U.S. health insurer has topped consensus estimates by an average of 6.44% over the last two quarters, including an 11.92% surprise last quarter with earnings of $7.23 per share versus a $6.46 estimate. UnitedHealth currently holds a Zacks Rank of 2, or Buy, and a positive Earnings ESP of +7.71%, a combination that Zacks research indicates produces a positive earnings surprise nearly 70% of the time. The company is scheduled to report its next quarterly results on July 16, 2026.